Allergen immunotherapy: An updated review of safety

Current Opinion in Allergy and Clinical Immunology

Volumn 17, Issue 1, 2017, Pages 55-59

  James, Christine ^a   Bernstein, David I ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Allergen immunotherapy; Safety; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGEN; VENOM;

ADVERSE DRUG REACTION; ALLERGIC REACTION; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG SAFETY; EVALUATION STUDY; EVIDENCE BASED PRACTICE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; ADVERSE EFFECTS; ANAPHYLAXIS; ANIMAL; COMPLICATION; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES; RISK; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANAPHYLAXIS; ANIMALS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; RISK;

EID: 85000919221     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000335     Document Type: Review

References (34)

1. Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010; 126: 778.
2. Soni A. Allergic rhinitis: Trends in use and expenditures, 2000 to 2005. Statistical Brief #204. Bethesda, MD: Agency for Healthcare Research and Quality; 2008.
3. Freeman J. Further observations of the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911; 2: 814-817.
4. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129: 717-725.
5. Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113: 1129.
6. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993; 92 (1 Pt 1): 6-15.
7. Coop CA, Tankersley MS. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann Allergy Asthma Immunol 2008; 101: 96-100.
8. Nelson BL, Dupont LA, Reid MJ. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts. Ann Allergy 1986; 56: 331-334.
9. Prigal SJ. A ten-year study of repository injections of allergens: Local reactions and their management. Ann Allergy 1972; 30: 529-535.
10. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000; 106: 840-843.
11. Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99: 82-86.
12. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004; 92: 225-227.
13. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 Suppl): S1-S55.
14. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAI and ACAAI surveillance study of subcutaneous immunotherapy, year 3: What practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol 2013; 110: 247-278.
15. Copenhaver CC, Parker A, Patch S, et al. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice. Ann Allergy Asthma Immunol 2011; 107: 441-447.
16. Windom H, Lockey R. An update on the safety of specific immunotherapy. Curr Opinion Allergy Clin Immunol 2008; 8: 571-576.
17. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013). Ann Allergy Asthma Immunol 2016; 116: 354-359.
18. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy year 2. Ann Allergy Asthma Immunol 2011; 107: 426.e1-431.e1.
19. Fitzhugh DJ, Bernstein DI. Should epinephrine auto-injectors be prescribed to all patients on subcutaneous immunotherapy? J Allergy Clin Immunol Pract 2016; 4: 862-867.
20. Cox L, Larenas-Linneman D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010; 125: 569-574; 574.e1-574.e7.
21. Rodriguez Del Rio P, Vidal C, Just J, et al. The European survey on adverse systemic reactions in allergen immunotherapy (EASSI): A pediatric assessment. Pediatr Allergy Immunol 2016. [Epub ahead of print]
22. Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy 2012; 67: 302-311.
23. Cox LS, Larenas Linneman D, Nolte H, et al. Sublingual immunotherapy: A comprehensive review. J Allergy Clin Immunol 2006; 117: 1021-1035.
24. Merck Sharp & Dohme Corporation. MK-7243 Timothy Grass Pollen Extract Tablets FDA Advisory Committee Briefing Document. Available at: Http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/AllergenicProductsAdvisoryCommittee/UCM378093.pdf. [Accessed 18 August 2016].
25. Stallergenes SA. Oralair Sublingual Tablets, Food and Drug Administration Allergenic Products Advisory Committee Briefing Document. Available at: Http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetings Materials/BloodVaccinesandOthersBiologics/AllergenicProductsAdvisory Committee/UCM377851.pdf. [Accessed 18 August 2016].
26. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014; 7: 6.
27. Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: A comprehensive review. J Allergy Clin Immunol 2006; 117: 1021-1035.
28. Maloney J, Durham S, Skoner D, et al. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. Allergy 2015; 70: 302-309.
29. Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: A large randomized controlled trial. Ann Allergy Asthma Immunol 2014; 112: 146-155.
30. Virchow J, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA 2016; 315: 1715-1725.
31. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite SLIT-tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2016; doi: 10.1016/j.jaci.2016.06.044. [Epub ahead of print]
32. Maloney J, Berman G, Gagnon R, et al. Sequential treatment initiation with Timothy Grass and Ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerated. J Allergy Clin Immunol Pract 2016; 4: 301-309.
33. Verburg M, Oldhoff JM, Klemans RJ, et al. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis. Eur Ann Allergy Clin Immunol 2015; 47: 192-196.
34. Korosec P, Ziberna K, Silar M, et al. Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy. Clin Exp Allergy 2015; 45: 1579-1589.